141 related articles for article (PubMed ID: 33096236)
21. Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache.
Kopruszinski CM; Navratilova E; Vagnerova B; Swiokla J; Patwardhan A; Dodick D; Porreca F
Cephalalgia; 2020 Jan; 40(1):68-78. PubMed ID: 31311288
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys.
Wiley JL; Huffman JW; Balster RL; Martin BR
Drug Alcohol Depend; 1995 Nov; 40(1):81-6. PubMed ID: 8746928
[TBL] [Abstract][Full Text] [Related]
23. Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
Hruba L; McMahon LR
J Pharmacol Exp Ther; 2017 Aug; 362(2):278-286. PubMed ID: 28533288
[TBL] [Abstract][Full Text] [Related]
24. Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.
Scherma M; Dessì C; Muntoni AL; Lecca S; Satta V; Luchicchi A; Pistis M; Panlilio LV; Fattore L; Goldberg SR; Fratta W; Fadda P
Neuropsychopharmacology; 2016 Apr; 41(5):1416-26. PubMed ID: 26388146
[TBL] [Abstract][Full Text] [Related]
25. Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats.
Robinson L; Hinder L; Pertwee RG; Riedel G
Psychopharmacology (Berl); 2003 Feb; 166(1):40-50. PubMed ID: 12488948
[TBL] [Abstract][Full Text] [Related]
26. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid.
Justinova Z; Mascia P; Wu HQ; Secci ME; Redhi GH; Panlilio LV; Scherma M; Barnes C; Parashos A; Zara T; Fratta W; Solinas M; Pistis M; Bergman J; Kangas BD; Ferré S; Tanda G; Schwarcz R; Goldberg SR
Nat Neurosci; 2013 Nov; 16(11):1652-61. PubMed ID: 24121737
[TBL] [Abstract][Full Text] [Related]
27. Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.
Hruba L; Ginsburg BC; McMahon LR
J Pharmacol Exp Ther; 2012 Sep; 342(3):843-9. PubMed ID: 22718500
[TBL] [Abstract][Full Text] [Related]
28. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.
Wiley JL; Barrett RL; Lowe J; Balster RL; Martin BR
Neuropharmacology; 1995 Jun; 34(6):669-76. PubMed ID: 7566504
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.
Gallo A; Bouchard C; Fortier E; Ducrot C; Rompré PP
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1534-45. PubMed ID: 25092427
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats.
Barrett RL; Wiley JL; Balster RL; Martin BR
Psychopharmacology (Berl); 1995 Apr; 118(4):419-24. PubMed ID: 7568628
[TBL] [Abstract][Full Text] [Related]
31. (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure.
Burkey RT; Nation JR
Exp Clin Psychopharmacol; 1997 Aug; 5(3):195-202. PubMed ID: 9260067
[TBL] [Abstract][Full Text] [Related]
32. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
Lile JA; Kelly TH; Pinsky DJ; Hays LR
Psychopharmacology (Berl); 2009 Apr; 203(2):241-50. PubMed ID: 19018520
[TBL] [Abstract][Full Text] [Related]
33. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
Wiley JL; Lowe JA; Balster RL; Martin BR
J Pharmacol Exp Ther; 1995 Oct; 275(1):1-6. PubMed ID: 7562536
[TBL] [Abstract][Full Text] [Related]
34. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
35. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
[TBL] [Abstract][Full Text] [Related]
36. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.
Compton DR; Gold LH; Ward SJ; Balster RL; Martin BR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1118-26. PubMed ID: 1335057
[TBL] [Abstract][Full Text] [Related]
37. Discriminative stimulus properties of Cannabis sativa terpenes in rats.
Carey LM; Ghodrati S; France CP
Behav Pharmacol; 2024 Jun; 35(4):161-171. PubMed ID: 38660819
[TBL] [Abstract][Full Text] [Related]
38. Natural (∆
Malyshevskaya O; Aritake K; Kaushik MK; Uchiyama N; Cherasse Y; Kikura-Hanajiri R; Urade Y
Sci Rep; 2017 Sep; 7(1):10516. PubMed ID: 28874764
[TBL] [Abstract][Full Text] [Related]
39. Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats.
Valiveti S; Agu RU; Hammell DC; Paudel KS; Earles DC; Wermeling DP; Stinchcomb AL
Eur J Pharm Biopharm; 2007 Feb; 65(2):247-52. PubMed ID: 17014999
[TBL] [Abstract][Full Text] [Related]
40. Δ
Gatch MB; Forster MJ
Psychopharmacology (Berl); 2018 Mar; 235(3):673-680. PubMed ID: 29138877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
